$3B Lilly Case Spotlights Drug Promoters' Labeling Quandary

Life Sciences Law360, Reprinted with permission

08/29/2014

Product Life Cycle, Life Sciences + Healthcare, and Class Actions + Mass Torts

In The News

In this article, James Huston comments on a Louisiana federal judge's decision to uphold a jury verdict awarding $3 billion in punitive damages against Eli Lilly & Co. in an Actos personal injury trial sending a stark warning that companies that co-promote a drug can be held liable for failing to warn of its potential risks, even if they're not responsible for changing the product's labeling.

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2019 Morrison & Foerster LLP. All rights reserved.